Clinical Trials Browser

Breast Neoplasms

HER2 Negative Breast Cancer Not Immediately Operated

Breast Neoplasms

Breast Neoplasms

Locoregional Recurrence

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Cancer Metastatic

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2 Negative Breast Cancer

Breast Neoplasms, Cardiovascular Diseases, Venous Thromboembolism

Carcinoma, Ovarian Epithelial, Breast Neoplasms

Anatomic Stage II Breast Cancer AJCC v8

Breast Neoplasms

Breast Neoplasms, Ovarian Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Advanced Breast Cancer

Breast Neoplasms, Neoplastic Cells, Circulating

Breast Neoplasms

Estrogen Receptor and/or Progesterone Receptor Positive

Advanced Breast Cancer

Breast Cancer Metastatic

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Clinical Trials

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

CALHYS

FAIM

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

RaPhLRR

Clinical and P

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NoLEEta

FELINE

DISCORDANT

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Ribociclib and Bicalutamide in AR+ TNBC

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

LEADER

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

CADILLAC

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

ARIADNE

ADAPTcycle

SAFIR 03

SELECT

BRAVE-Cyclin

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

HARMONIA

CHARGE

RIBOLARIS

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

FACILE

PALMARES-2

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

MAINTAIN

LEANORA

Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer

RibOB

NEOLETRIB

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Detect V / CHEVENDO (Chemo vs. Endo)

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer

AMICA

CAPTOR-BC

ORACLE-RIPA

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer